CytRx Corporation, a biopharmaceutical research and development company, specializes in oncology. Its drug development pipeline includes INNO-206, which is in Phase Ib clinical trial and is completing Phase Ib/II clinical trial for the treatment for soft tissue sarcomas; and tamibarotene that in Phase IIb clinical trial for the treatment of non-small-cell lung cancer and is in a clinical…More trial as a treatment for acute promyelocytic leukemia.
CytRX Corporation does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.
Shipping Information
Please fill out the form below and click "Place Order" to complete your order.